Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer.
Aggressive prostate cancer
Decipher score
Genomic risk
Grade group 4
Grade group 5
High-grade prostate cancer
Immune content
Immunogenomics
Lethal outcomes
Journal
European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
25
06
2020
accepted:
20
11
2020
pubmed:
12
12
2020
medline:
19
4
2022
entrez:
11
12
2020
Statut:
ppublish
Résumé
Grade group 4 and 5 (GG-45) prostate cancer (PCa) patients are at the highest risk of lethal outcomes, yet lack genomic risk stratification for prognosis and treatment selection. Here, we assess whether transcriptomic interactions between tumor immune content score (ICS) and the Decipher genomic classifier can identify most lethal subsets of GG-45 PCa. We utilized whole transcriptome data from 8071 tumor tissue (6071 prostatectomy and 2000 treatment-naïve biopsy samples) to derive four immunogenomic subtypes using ICS and Decipher. When compared across all grade groups, GG-45 samples had the highest proportion of most aggressive subtype-ICS
Identifiants
pubmed: 33303244
pii: S0302-2838(20)30939-8
doi: 10.1016/j.eururo.2020.11.038
pmc: PMC9838823
mid: NIHMS1861596
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
325-330Subventions
Organisme : NCI NIH HHS
ID : P20 CA233255
Pays : United States
Informations de copyright
Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Références
Lancet Oncol. 2016 Nov;17(11):1612-1620
pubmed: 27743920
J Natl Cancer Inst. 2019 Mar 1;111(3):301-310
pubmed: 30321406
Eur Urol. 2016 Jan;69(1):157-65
pubmed: 26058959
Methods Mol Biol. 2018;1711:243-259
pubmed: 29344893
Prostate Cancer Prostatic Dis. 2016 Dec;19(4):374-379
pubmed: 27574020
Eur Urol. 2016 Mar;69(3):428-35
pubmed: 26166626
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):489-96
pubmed: 19735873
Eur Urol. 2020 Sep;78(3):327-332
pubmed: 32461072